See What HealthDay Can Do For You
Contact Us

Drug Shows Promise for Skin Cancer Prevention Treatment

Styrylquinazoline compound CP-31398 targets mutant tumor suppressor p53

WEDNESDAY, Dec. 5 (HealthDay News) -- A drug that targets a mutant cancer protein can prevent and treat ultraviolet light-induced skin tumors in a non-immunodeficient mouse model and in human skin carcinoma cells, according to a study in the Dec. 3 issue of the Journal of Clinical Investigation.

Xiuwei Tang, from Columbia University College of Physicians and Surgeons in New York City, and colleagues investigated the effect of styrylquinazoline compound CP-31398, which restores the tumor suppressor functions of mutant p53 protein, in mice after treatment with ultraviolet B radiation and in A431 cells, human skin carcinoma cells that carry mutant p53.

The researchers found that CP-31398 affected various signal transduction pathways involving p53 and p53-targeted proteins. Treatment was followed by p53 dependent cell cycle arrest and apoptosis after ultraviolet radiation in wild-type (p53 positive) mice but not in mice deficient in p53. Similar results were seen in the human A431 cells that expressed mutant p53. CP-31398 was effective at treating skin tumors as well as preventing them, according to the study.

The work "is an elegant study that suggests CP-31398 topical application may be active in skin cancer prevention following ultraviolet light exposure and may provide an effective therapy after cancer development," Wafik S. El-Deiry, M.D., Ph.D., from the University of Pennsylvania School of Medicine in Philadelphia, writes in an accompanying editorial.

Full Text

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.